82
Trials as lead sponsor
Most active programmes
The drugs appearing most often across argenx's recently active trials. Comparator arms are excluded.
- Efgartigimod PH20 SC14 trials
- efgartigimod PH20 SC9 trials
- Efgartigimod IV8 trials
- Empasiprubart IV7 trials
- ARGX-1137 trials
- Efgartigimod6 trials
Upcoming readouts
Next primary completion dates among argenx's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Sept 2026ADAPT Jr SC: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With General…Phase 2
- Feb 2027eSScape: A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclero…Phase 2
- Mar 2027ADAPT Jr: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intra…Phase 2
- Sept 2027emvigorate: A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPhase 3
- Oct 2027emnergize: A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPhase 3
- Mar 2028ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod …Phase 2
Top therapeutic areas
Conditions studied most often across argenx's recently active trials.
- Generalized Myasthenia Gravis11 trials
- gMG7 trials
- Myasthenia Gravis6 trials
- CIDP5 trials
- Primary Immune Thrombocytopenia5 trials
- Chronic Inflammatory Demyelinating Polyneuropathy3 trials
argenx trials
The 50 most significant of argenx's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| ADAPT-EARLYA Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)NCT06909214Efgartigimod PH20 SC | Phase 4 | Locked · track to reveal | OngoingRecruiting | 30 est. | Aug 2026 |
| ReALiSeA Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)NCT06441682ARGX-119 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 60 est. | Aug 2026 |
| EmpassionA Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyNCT06742190Empasiprubart | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 154 est. | Sept 2026 |
| ADAPT Jr SCA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisNCT06392386Efgartigimod PH20 SC | Phase 2 | Locked · track to reveal | OngoingRecruiting | 12 est. | 30 Sept 2026 |
| ADVANCE SC+A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaNCT04812925efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 173 est. | 1 Oct 2026 |
| empacificA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisNCT06284954Empasiprubart IV | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 3 est. | Nov 2026 |
| ALKIVIAA Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.NCT05523167EFG PH20 SC | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 265 est. | 1 Dec 2026 |
| A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult ParticipantsNCT07673601Adimanebart IV | Phase 1 | Not yet scored | OngoingRecruiting | 52 est. | Dec 2026 |
| A Study to Assess the Safety of ARGX-124 in Healthy VolunteersNCT07377396ARGX-124 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 104 est. | 31 Dec 2026 |
| eSScapeA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisNCT06655155Efgartigimod PH20 SC | Phase 2 | Locked · track to reveal | OngoingRecruiting | 81 est. | Feb 2027 |
| ADAPT JrEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisNCT04833894Efgartigimod IV | Phase 2 | Locked · track to reveal | OngoingRecruiting | 12 est. | Mar 2027 |
| A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsNCT07612020empasiprubart SC AI | Phase 1 | Locked · track to reveal | OngoingRecruiting | 130 est. | Mar 2027 |
| ADHERE+A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)NCT04280718Efgartigimod PH20 SC | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 229 est. | 30 Apr 2027 |
| A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4NCT06078553 | — | Not yet scored | OngoingRecruiting | 100 est. | Jun 2027 |
| UnityA Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeNCT06684847Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 631 est. | Jul 2027 |
| A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)NCT06436742ARGX-119 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 16 est. | 24 Aug 2027 |
| emvigorateA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPNCT06920004empasiprubart | Phase 3 | Locked · track to reveal | OngoingRecruiting | 218 est. | Sept 2027 |
| emnergizeA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPNCT07091630Empasiprubart IV | Phase 3 | Locked · track to reveal | OngoingRecruiting | 160 est. | 7 Oct 2027 |
| ADAPT Forward2ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisNCT07673627Empasiprubart IV | Phase 2 | Not yet scored | OngoingNot yet recruiting | 40 est. | Oct 2027 |
| POEMAA Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in ItalyNCT07595653 | — | Not yet scored | OngoingRecruiting | 100 est. | Nov 2027 |
| ShamrockA Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)NCT06503731Efgartigimod PH20 SC - prefilled syringe | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 33 est. | Nov 2027 |
| EmpaSoundA Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor NeuropathyNCT07610564Empasiprubart IV | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 60 est. | 1 Feb 2028 |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodNCT07284420Efgartigimod IV | Phase 2 | Locked · track to reveal | OngoingRecruiting | 70 est. | 7 Mar 2028 |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia GravisNCT07294170Efgartigimod IV | — | Not yet scored | OngoingRecruiting | 70 est. | 7 Mar 2028 |
| emlightA Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating PolyradiculoneuropathyNCT07638566Empasiprubart IV | Phase 2 | Not yet scored | OngoingNot yet recruiting | 6 est. | Apr 2028 |
| VitaliThyA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.NCT07596849efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingRecruiting | 230 est. | Jun 2028 |
| VitaliThyA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseNCT07570316Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingRecruiting | 230 est. | Jun 2028 |
| advance NEXTA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaNCT06544499Efgartigimod IV | Phase 3 | Locked · track to reveal | OngoingRecruiting | 69 est. | Jun 2028 |
| ALKIVIA+A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyNCT05979441Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 240 est. | Sept 2028 |
| Advance JrA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)NCT07194850Efgartigimod IV | Phase 2 | Locked · track to reveal | OngoingRecruiting | 24 est. | Oct 2028 |
| iMMersioNA Prospective Longitudinal Study in Adults With Multifocal Motor NeuropathyNCT05988073 | — | Not yet scored | OngoingActive, not recruiting | 413 est. | 31 Dec 2028 |
| PolarisA Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsNCT07583641Efgartigimod PH20 (ARGX-113) SC | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 170 est. | 20 Jan 2029 |
| SparkleA Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular AtrophyNCT07287982ARGX-119 IV | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | 28 May 2029 |
| ADAPT Jr +Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisNCT05374590Efgartigimod IV or Efgartigimod PH20 SC | Phase 2 | Locked · track to reveal | OngoingEnrolling by invitation | 12 est. | Sept 2029 |
| ARDA+A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor NeuropathyNCT05405361ARGX-117 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 51 est. | 30 Sept 2029 |
| Real-World Efgartigimod Effectiveness in CIDP: A Prospective StudyNCT07264426Efgartigimod PH20 SC | — | Not yet scored | OngoingRecruiting | 200 est. | Oct 2029 |
| A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.NCT06299748Efgartigimod | — | Not yet scored | OngoingRecruiting | 279 est. | Jan 2033 |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod AlfaNCT06298565efgartigimod | — | Not yet scored | OngoingRecruiting | 680 est. | Jun 2034 |
| A Study to Assess the Safety of ARGX-213 in Healthy VolunteersNCT06968338ARGX-213 | Phase 1 | Locked · track to reveal | Completed | 88 est. | 20 Mar 2026 |
| ADVANCE+A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).NCT04225156efgartigimod | Phase 3 | Locked · track to reveal | Completed | 101 est. | 11 Mar 2026 |
| A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SCNCT06637072Efgartigimod PH20 SC | Phase 4 | Locked · track to reveal | Completed | 23 est. | 19 Feb 2026 |
| ADAPT oculusA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisNCT06558279Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 141 est. | 12 Jan 2026 |
| UplighTEDA Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.NCT06307626Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | StoppedTerminated | 105 est. | 15 Dec 2025 |
| UplighTEDA Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseNCT06307613Efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | StoppedTerminated | 102 est. | 15 Dec 2025 |
| VARVARAARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionNCT05907096ARGX-117 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 103 est. | 16 Oct 2025 |
| A Study to Assess the Safety of ARGX-109 in Healthy VolunteersNCT06799416ARGX-109 | Phase 1 | Locked · track to reveal | Completed | 40 est. | 8 Aug 2025 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)NCT05810948efgartigimod IV | Phase 2 | Locked · track to reveal | Completed | 73 est. | 2 Jul 2025 |
| ADAPT SERONA Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisNCT06298552Efgartigimod IV | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 119 est. | 30 Jun 2025 |
| BALLAD+A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidNCT05681481efgartigimod PH20 SC | Phase 3 | Locked · track to reveal | StoppedTerminated | 64 est. | 20 Mar 2025 |
| Rho plusOpen-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's SyndromeNCT06203457Efgartigimod | Phase 2 | Locked · track to reveal | Completed | 24 est. | 3 Feb 2025 |